Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 09:27 ET | Source: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...
October 21, 2025 04:00 ET | Source: AKAMPION

selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker...
October 02, 2025 09:38 ET | Source: Research and Markets

Dermatology CRO Market Trends Analysis Report 2025-2033: Opportunities Lie in Decentralized Trials, AI, Personalized Medicine, and Expanding Presence

Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "Dermatology CRO Market Size, Share & Trends Analysis Report by Type (Drug Discovery, Preclinical, Clinical), by Service (Clinical Monitoring,...
September 11, 2025 07:56 ET | Source: Janssen Cilag International NV

Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints....
September 10, 2025 09:54 ET | Source: Research and Markets

68 Plaque Psoriasis (Country) Market Analysis and Sales Forecast to 2030

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: 68-Market Analysis and Sales Forecast - Update (2025)" report has been added to ResearchAndMarkets.com's offering. This report...
September 07, 2025 08:30 ET | Source: Junshi Biosciences

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study
August 13, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 21, 2025 04:49 ET | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Trends Report 2025 with Directory of 474 Deals Since 2016 - Company A-Z, Therapy Focus, Upfront, Milestone, Royalties

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the...
May 29, 2025 07:55 ET | Source: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
May 28, 2025 09:20 ET | Source: Research and Markets

Vitiligo Market Growth Trends and Forecast Report 2025-2033 - Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access

Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The...